S

SoftOx Solutions AS
OSE:SOFTX

Watchlist Manager
SoftOx Solutions AS
OSE:SOFTX
Watchlist
Price: 0.056 NOK -5.08%
Market Cap: 130.5m NOK

Relative Value

The Relative Value of one SOFTX stock under the Base Case scenario is 0.018 NOK. Compared to the current market price of 0.056 NOK, SoftOx Solutions AS is Overvalued by 68%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SOFTX Relative Value
Base Case
0.018 NOK
Overvaluation 68%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
65
vs Industry
19
Median 3Y
11.1
Median 5Y
23.4
Industry
2.6
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-5.5
Industry
21.6
vs History
vs Industry
42
Median 3Y
-1.6
Median 5Y
-5.1
Industry
16.5
vs History
vs Industry
26
Median 3Y
-1.7
Median 5Y
-5.3
Industry
22.5
vs History
76
vs Industry
58
Median 3Y
1.8
Median 5Y
3.6
Industry
2.3
vs History
65
vs Industry
19
Median 3Y
13.2
Median 5Y
24.4
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
54
Median 3Y
-3.2
Median 5Y
-4.7
Industry
13
vs History
vs Industry
51
Median 3Y
-2.8
Median 5Y
-4.4
Industry
16.6
vs History
vs Industry
43
Median 3Y
-1.2
Median 5Y
-4.6
Industry
15.8
vs History
vs Industry
27
Median 3Y
-1.5
Median 5Y
-4.9
Industry
19.1
vs History
65
vs Industry
52
Median 3Y
1.3
Median 5Y
2.5
Industry
1.9

Multiples Across Competitors

SOFTX Competitors Multiples
SoftOx Solutions AS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
SoftOx Solutions AS
OSE:SOFTX
132.2m NOK 11.9 -8.1 -9 -7.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.6 39.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
515.3B USD 5.6 20.5 16.8 21.7
CH
Roche Holding AG
SIX:ROG
255.9B CHF 4.2 27.2 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
209.8B GBP 4.8 29.8 108.2 158.3
CH
Novartis AG
SIX:NOVN
208.9B CHF 4.7 18.2 11.6 14.9
US
Merck & Co Inc
NYSE:MRK
249.4B USD 3.9 13.1 9.3 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.5 9.5 11
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
150.3B USD 2.4 15.3 7.7 10.5
P/E Multiple
Earnings Growth PEG
NO
S
SoftOx Solutions AS
OSE:SOFTX
Average P/E: 24
Negative Multiple: -8.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.5
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.2
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.3
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
S
SoftOx Solutions AS
OSE:SOFTX
Average EV/EBITDA: 438.9
Negative Multiple: -9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.6
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.8
9%
1.9
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.6
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
1%
7.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
S
SoftOx Solutions AS
OSE:SOFTX
Average EV/EBIT: 1 881.3
Negative Multiple: -7.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
8%
1.3